Biopreventative: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://biopreventative.com in August 2025 and has observed that your website offers various compounded drug products, including tadalafil. As described below, your claim concerning your compounded tadalafil products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claim concerning your compounded tadalafil products appears on your website:”

2. 2

   ““Tadalafil (commonly known as Cialis) is a compound medication.””

3. 3

   “Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

biopreventative.com returned a live site on 2026-08-09 titled "Bio Preventative", advertising "NEW PATIENTS GET $100 OFF FIRST MONTH PURCHASE" with semaglutide and tirzepatide weight-loss pages, a states-we-service page and a working contact flow — an operating seller. Neither "tadalafil" nor "Cialis" appears in the homepage as fetched; the cited page was not re-checked beyond that.

This is the low-water mark of the roster, and that is exactly what makes it worth reading. "Tadalafil (commonly known as Cialis) is a compound medication" is the sort of sentence a careful writer produces when trying to be helpful — it names the molecule, says plainly that the product is compounded, and adds the brand only so a reader knows what drug is being discussed. FDA still cited it. Set against the rest of this dataset, where sellers wrote "generic Ozempic" and invented approval dates, it establishes where the line actually sits: not at exaggeration, but at any construction that lets a compounded product borrow an approved product's name. Two practical points follow. First, the presence of a warning letter tells you nothing on its own about how strong the underlying claim was — the letters in this roster range from a definition to a fabricated approval history, and they all look identical in a list. Second, this is the only tadalafil-only letter here, a useful reminder that the same rule governs erectile-dysfunction compounding as governs GLP-1s, even though the GLP-1 letters get the attention. Nothing in the letter concerns dosing, sourcing, or safety.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Biopreventative failed to respond.